Tanke Biosciences Corporation (TNBI)

Tanke Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2022	FY 2021	FY 2012	FY 2011	FY 2010
Period Ending	Dec 31, 2022	Dec 31, 2021	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010
Revenue	-	-	28.56	23.83	20.1
Revenue Growth (YoY)	-	-	19.84%	18.58%	65.15%
Cost of Revenue	-	-	18.62	15.06	12.7
Gross Profit	-	-	9.94	8.77	7.4
Selling, General & Admin	0.13	0.67	5.25	6.95	2.72
Other Operating Expenses	-	-	-	-	0.26
Operating Expenses	0.13	0.67	5.41	7.03	3.03
Operating Income	-0.13	-0.67	4.53	1.74	4.37
Interest Expense	-0	-0	-4.22	-3.83	-0.1
Interest & Investment Income	-	-	0.3	0.1	0
Currency Exchange Gain (Loss)	-	-	-	-	-0
Other Non Operating Income (Expenses)	0.03	-0.05	-0	-0.46	-
Pretax Income	-0.1	-0.72	0.6	-2.45	4.28
Income Tax Expense	-	-	0.83	0.68	0.58
Earnings From Continuing Operations	-0.1	-0.72	-0.23	-3.14	3.69
Minority Interest in Earnings	-	-	0.02	-	-0.96
Net Income	-0.1	-0.72	-0.21	-3.14	2.74
Net Income to Common	-0.1	-0.72	-0.21	-3.14	2.74
Net Income Growth	-	-	-	-	37.44%
Shares Outstanding (Basic)	12	13	13	13	11
Shares Outstanding (Diluted)	12	13	13	13	11
Shares Change (YoY)	-2.12%	-4.34%	1.84%	21.62%	-
EPS (Basic)	-0.01	-0.06	-0.02	-0.24	0.25
EPS (Diluted)	-0.01	-0.06	-0.02	-0.24	0.25
EPS Growth	-	-	-	-	37.44%
Free Cash Flow	-0.06	-0	-2.04	2.95	1.41
Free Cash Flow Per Share	-0.01	-	-0.15	0.23	0.13
Gross Margin	-	-	34.82%	36.80%	36.82%
Operating Margin	-	-	15.87%	7.30%	21.76%
Profit Margin	-	-	-0.74%	-13.16%	13.63%
Free Cash Flow Margin	-	-	-7.14%	12.39%	7.04%
EBITDA	-	-	5.17	2.14	4.51
EBITDA Margin	-	-	18.09%	8.98%	22.44%
D&A For EBITDA	-	-	0.64	0.4	0.14
EBIT	-0.13	-0.67	4.53	1.74	4.37
EBIT Margin	-	-	15.87%	7.30%	21.76%
Effective Tax Rate	-	-	138.00%	-	13.62%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.